0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

β-Blockers after Myocardial Infarction: Influence of First-Year Clinical Course on Long-Term Effectiveness

Catherine M. Viscoli, PhD; Ralph I. Horwitz, MD; and Burton H. Singer, PhD
[+] Article and Author Information

From Yale University School of Medicine, New Haven, Connecticut. Requests for Reprints: Ralph I. Horwitz, MD, Yale University School of Medicine, Room IE-61, SHM, P.O. Box 3333, New Haven, CT 06510. Acknowledgments: The authors thank the BHAT investigators, particularly the project director, Robert Byington, for providing access to the trial data. Grant Support: In part by U.S. Public Health Service training grant 5-T32-HL07428 (Dr. Viscoli).


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1993;118(2):99-105. doi:10.7326/0003-4819-118-2-199301150-00004
Text Size: A A A

Objective: To develop a strategy for evaluating drug efficacy over time that accounts for heterogeneous clinical courses evolving after initiation of therapy and to demonstrate its use in assessing the long-term therapeutic benefit of propranolol after myocardial infarction.

Design: Analysis of data from the Beta-Blocker in Heart Attack Trial (BHAT), a randomized, double-blind, placebo-controlled trial that enrolled patients from 1978 to 1980 and followed participants for vital status to April 1982.

Setting: Thirty-one clinical centers in the United States and Canada.

Patients: Eligible patients included 3297 men and women 30 to 69 years of age who survived 1 year after trial entry.

Intervention: Patients were classified as being on treatment at 12 months after randomization if they were receiving β-blocker therapy at the 12-month visit and off treatment if they were not receiving β-blocker therapy at that time.

Outcome Measure: Vital status evaluated at 720 days of follow-up.

Results: A total of 2914 patients (88%) was classified as being at lower risk (strata I and II). For these patients, survival curves by treatment at 12 months were virtually indistinguishable. Among the 383 patients categorized as being at high risk on the basis of recurrent ischemic events, arrhythmias, congestive heart failure, or severe comorbidity during the first 12 months, the use of β-blockers was associated with a 43% proportional decline in the subsequent risk for death (P = 0.01 by log-rank test).

Conclusions: In patients who survived to 1 year with low- to moderate-risk clinical courses, β-blocker therapy did not have long-term beneficial effect. In contrast, among patients who had a high-risk clinical course during the first year, β-blockers significantly reduced mortality in the follow-up period.

Figures

Grahic Jump Location
Figure 1.
Long-term mortality experience by risk stratum.

Solid line = On β-blocker therapy. Dashed line = Off β-blocker therapy.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)